- S. Korea's Yoon: from rising star to historic arrest
- Ominous Alcaraz sweeps into Australian Open third round
- 'Queen Wen' deposed in huge shock at Australian Open
- Vigilante fire clean-up launched by local Los Angeles contractor
- Zheng dumped out in huge shock as shaky Sabalenka battles through
- Asian equities mixed as US inflation, China data loom
- 'Queen Wen' Zheng deposed in huge shock at Australian Open
- Renewed US trade war threatens China's 'lifeline'
- China's economy seen slowing further in 2024: AFP survey
- Shaky Sabalenka overcomes serve struggles to stay alive in Melbourne
- South Korea's six weeks of political chaos
- Japan's tourism boom prices out business travellers
- What is the pink stuff coating fire-ravaged Los Angeles?
- Mediators make final push for Gaza truce deal
- Musk, Bezos, Zuckerberg to attend Trump inauguration: report
- Federal probe begins into deadly Los Angeles fires
- 'We may look easy-going, but...' Canadians veto Trump's merger plan
- Is obesity a disease? Sometimes but not always, experts decide
- Biden issues land protections after LA fires delay ceremony
- Cuba to free over 550 prisoners after removal from US terror list
- Williams, Vine vie for season-opening Tour Down Under crown
- Maresca 'concerned' as Chelsea winless run stretches to five games
- 'Outstanding' Liverpool deserved more than Forest draw: Slot
- Guardiola laments Man City decision-making in Brentford collapse
- Marseille dumped out of French Cup on penalties
- Liverpool frustrated by Forest, Man City blow late lead at Brentford
- Djokovic, Sabalenka chase history as Australian Open hits round two
- Golf star Woods pledges support amid 'unimaginable loss' of LA fires
- Liverpool held by Forest, Man City blow late lead at Brentford
- Cuba to free 553 prisoners after removal from US terror list
- Leverkusen win to go one point behind Bayern, Kiel down Dortmund
- Jota rescues leaders Liverpool in Forest draw
- Title chasers Atalanta held by Juve, Milan hand Conceicao maiden Serie A win
- Man City blow late lead at Brentford, Chelsea held by Bournemouth
- Rast charges through on second run to win Flachau slalom
- Grimaldo scores as Leverkusen go one point behind Bayern, Dortmund lose
- Starbucks shift on non-paying visitors stirs debate in US
- Clashes as S. Korean investigators attempt to arrest President Yoon
- US, Japanese lunar landers set to launch on single rocket
- Boeing 2024 plane deliveries tumble on labor, safety woes
- US removes Cuba from state sponsors of terror list
- Argentine annual inflation nosedives, in boost for Milei
- S. Korea investigators arrive in new attempt to arrest President Yoon
- Pressure builds on Dortmund boss Sahin after loss at Kiel
- Meta to lay off 3,600 employees in performance-based cuts
- Venezuela restricts diplomats from 'hostile' European countries
- Trump's Pentagon pick grilled by senators as cabinet hearings begin
- From ban to buyout: What next for TikTok in the US?
- Lazio sack doc who performed far-right falconer's penis op: club owner
- Mexico hails $5 bn Amazon investment in face of Trump threats
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
G.Schulte--BTB